Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Full-Year 2024 Financial Results ...
High dose and low dose of TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in all pediatric, adolescent and adult patients treated (high dose, n=6; low dose, n=4 ...
Rolling Out55 分
Generational health patterns every family should discuss
Discover the most common hereditary health conditions, their early warning signs, and how knowing your family medical history ...
Regeneron Pharmaceuticals, Inc.: Odronextamab BLA Accepted for FDA Review for the Treatment ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission ...